Novartis India Ltd
NOVARTINDNovartis India Ltd
NOVARTIND
Price Chart
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 30.49 | 3.58 | 2.32% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.27 | 6.55 | 0.51% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Novartis India Limited manufactures drugs, medicines and allied products. The Company is engaged in the wholesale of pharmaceuticals and medical goods.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Mankind Pharma Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 896.45 | 727.22 | 735.72 | 568.94 | 474.39 | 414.44 | 433.06 | 436.85 | 396.75 | 398.22 | ||||||||||
Raw Materials | 292.88 | 321.33 | 214.55 | 202.60 | 180.49 | 135.88 | 187.26 | 199.34 | 189.98 | 272.19 | ||||||||||
| Power & Fuel Cost | 4.43 | 1.77 | 2.56 | 1.79 | 1.27 | 0.53 | 0.53 | 0.35 | 0.18 | |||||||||||
| Employee Cost | 156.66 | 139.30 | 144.53 | 117.11 | 113.87 | 108.51 | 101.89 | 35.64 | 22.96 | |||||||||||
| Selling & Administrative Expenses | 123.51 | 126.89 | 122.50 | 107.03 | 80.43 | 55.73 | 57.61 | 48.00 | 33.78 | |||||||||||
| Operating & Other expenses | 78.10 | 41.89 | 86.00 | 49.87 | 50.16 | 53.91 | 75.11 | 30.33 | 22.91 | |||||||||||
EBITDA | 240.87 | 96.04 | 165.58 | 90.54 | 48.17 | 59.88 | 10.66 | 123.19 | 126.94 | 126.03 | ||||||||||
| Depreciation/Amortization | 3.49 | 3.59 | 2.53 | 3.18 | 13.14 | 12.16 | 9.65 | 6.06 | 2.61 | 1.54 | ||||||||||
| PBIT | 237.38 | 92.45 | 163.05 | 87.36 | 35.03 | 47.72 | 1.01 | 117.13 | 124.33 | 124.49 | ||||||||||
| Interest & Other Items | 0.21 | 0.72 | 5.53 | 1.59 | 6.39 | 7.68 | 4.83 | 1.75 | 1.49 | 0.61 | ||||||||||
| PBT | 237.17 | 91.73 | 157.52 | 85.77 | 28.64 | 40.04 | -3.82 | 115.38 | 122.84 | 123.88 | ||||||||||
| Taxes & Other Items | 38.88 | 34.51 | 79.16 | 34.00 | 18.56 | 19.14 | -0.10 | 12.02 | 37.65 | 36.48 | ||||||||||
| Net Income | 198.29 | 57.22 | 78.36 | 51.77 | 10.08 | 20.90 | -3.72 | 103.36 | 85.19 | 87.40 | ||||||||||
| EPS | 62.04 | 19.04 | 29.66 | 20.97 | 4.08 | 8.46 | -1.51 | 41.86 | 34.50 | 35.40 | ||||||||||
| DPS | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 47.50 | 25.00 | 25.00 | ||||||||||
| Payout ratio | 0.16 | 0.53 | 0.34 | 0.48 | 2.45 | 1.18 | — | 1.13 | 0.72 | 0.71 |
Company Updates
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Novartis India Ltd | 31.29 | 3.58 | 2.32% |
| Sun Pharmaceutical Industries Ltd | 45.34 | 6.47 | 0.75% |
| Cipla Ltd | 31.21 | 4.80 | 0.82% |
| Torrent Pharmaceuticals Ltd | 65.38 | 15.80 | 0.88% |
Price Comparison
Compare NOVARTIND with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 1 Mutual Funds holding Novartis India Ltd
| Funds (Top 1) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
Bandhan BSE Healthcare Index Fund Direct Plan-Growth Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.0004% | Percentage of the fund’s portfolio invested in the stock 0.06% | Change in the portfolio weight of the stock over the last 3 months 0.06% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 92/102 (-1) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividend Cuts
NOVARTIND has increased or maintained dividend levels over the last 5 years
Dividend Yield
Current dividend yield is 2.31%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹23.14 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJul 23, 2024
Dividend/Share
₹25.00
Ex DateEx Date
Jul 23, 2024
Cash Dividend
Ex DateEx DateJul 20, 2023
Dividend/Share
₹37.50
Ex DateEx Date
Jul 20, 2023
Cash Dividend
Ex DateEx DateJul 20, 2023
Dividend/Share
₹10.00
Ex DateEx Date
Jul 20, 2023
Cash Dividend
Ex DateEx DateJul 20, 2022
Dividend/Share
₹10.00
Ex DateEx Date
Jul 20, 2022
Cash Dividend
Ex DateEx DateAug 17, 2021
Dividend/Share
₹10.00
Ex DateEx Date
Aug 17, 2021
Net profit of Novartis India declined 13.81% to Rs 20.41 crore in the quarter ended September 2024 as against Rs 23.68 crore during the previous quarter ended September 2023. Sales rose 10.60% to Rs 87.11 crore in the quarter ended September 2024 as against Rs 78.76 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales87.1178.76 11 OPM %20.6321.47 - PBDT28.1533.08 -15 PBT27.5632.43 -15 NP20.4123.68 -14 Powered by Capital Market - Live
Novartis India will hold a meeting of the Board of Directors of the Company on 25 October 2024.Powered by Capital Market - Live
Novartis India standalone net profit rises 27.05% in the June 2024 quarter
Net profit of Novartis India rose 27.05% to Rs 25.74 crore in the quarter ended June 2024 as against Rs 20.26 crore during the previous quarter ended June 2023. Sales rose 1.87% to Rs 92.29 crore in the quarter ended June 2024 as against Rs 90.60 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales92.2990.60 2 OPM %25.9719.17 - PBDT34.2329.33 17 PBT33.6827.77 21 NP25.7420.26 27 Powered by Capital Market - Live
RMI Scanner generates new ‘buy’ signal in these 4 stocks; do you own any?
Dr. Reddy’s Hits Life High On Reports Of Acquiring Novartis India
Novartis Starts ‘Strategic Review’ Of India Listed Business Amid Reports Of Sale Talks
Novartis India standalone net profit rises 161.40% in the September 2022 quarter
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of -6.96%, vs industry avg of 9.03%
Decreasing Market Share
Over the last 5 years, market share decreased from 0.26% to 0.11%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 10.47%, vs industry avg of 15.28%